Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Erik Wallström(Novartis (Switzerland)), Olaf Stüve(Southwestern Medical Center), Frank Dahlke(Ophthalmology Clinic), Ludwig Kappos(University Hospital of Basel), Lixin Zhang Auberson(Novartis (Switzerland)), François Mercier(Novartis (Switzerland)), H. Pöhlmann(Novartis (Switzerland)), David K.B. Li(University of British Columbia), Hans-Peter Hartung(The University of Sydney), Mark S. Freedman(University of Ottawa), Bernhard Hemmer(Munich Cluster for Systems Neurology), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 233
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k